The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Olsalazine     5-[(2E)-2-(3-carboxy-4-oxo-1- cyclohexa-2,5...

Synonyms: CHEMBL425, AC1NUWCP, CHEMBL571540
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Azodisal

  • Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties [1].
  • When the colitis activity at study entry was compared with that observed at the completion of the study period, statistically significant or nearly significant improvement was demonstrated within the combined olsalazine group (p = 0.01) and within patient groups receiving olsalazine at daily doses of 1.5 g (p = 0.04) and 3 g (p = 0.055) [2].
  • Analysis restricted to 64 patients still in remission at 1 year and 18 with relapses also showed a significant difference in relapse rate (olsalazine 5/42 [12%] vs mesalazine 13/40 [33%]; p = 0.024) [3].
  • Four patients were withdrawn because of adverse reactions: 2 developed a skin rash while receiving olsalazine and 2 had diarrhea, one while on olsalazine and the other while on placebo [2].
  • RESULTS: No differences in the frequency of termination due to relapse or time to termination due to relapse were noted between the two treatment groups (olsalazine 48.5% v placebo 45%) for either colitis or ileocolitis [4].

High impact information on Azodisal


Chemical compound and disease context of Azodisal


Biological context of Azodisal

  • Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis [14].
  • Olsalazine 250 mg four times daily significantly accelerated gastric emptying (mean +/- SD; 45.3 +/- 24.2 min v 67.3 +/- 33.1 min, p less than 0.05), mouth to caecum transit time (242 +/- 41 min v 325 +/- 33 min, p less than 0.02) and whole gut transit time (60.5 +/- 26 h v 37.8 +/- 17.8 h, p less than 0.05) [15].
  • Neither parent compound (SAZ, olsalazine) nor the pharmacologically inactive metabolite (SP) were effective in attenuating the lipid peroxidation at concentrations up to 100 microM [16].
  • We found that the concentrations necessary to inhibit the N-nitrosation reaction by 50% (IC50) were 25, 50 and 100 microM for 5-ASA, olsalazine (dimeric 5-ASA) and sulfasalazine, respectively [17].
  • METHODS: The local and systemic bioavailability of 5-ASA from a controlled release 5-ASA preparation (Pentasa--2, 4 or 6 g/day) was investigated and compared with the azo-bond 5-ASA preparation olsalazine (Dipentum--2 g/day) in 13 healthy volunteers during steady state conditions [18].

Anatomical context of Azodisal


Associations of Azodisal with other chemical compounds


Gene context of Azodisal


Analytical, diagnostic and therapeutic context of Azodisal


  1. Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties. Sandberg-Gertzén, H., Järnerot, G., Kraaz, W. Gastroenterology (1986) [Pubmed]
  2. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. Meyers, S., Sachar, D.B., Present, D.H., Janowitz, H.D. Gastroenterology (1987) [Pubmed]
  3. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Courtney, M.G., Nunes, D.P., Bergin, C.F., O'Driscoll, M., Trimble, V., Keeling, P.W., Weir, D.G. Lancet (1992) [Pubmed]
  4. Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study. Mahmud, N., Kamm, M.A., Dupas, J.L., Jewell, D.P., O'Morain, C.A., Weir, D.G., Kelleher, D. Gut (2001) [Pubmed]
  5. Mesalazine versus olsalazine for prophylaxis of ulcerative colitis relapse. Record, C.O., Macrae, K. Lancet (1992) [Pubmed]
  6. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. van Staa, T.P., Card, T., Logan, R.F., Leufkens, H.G. Gut (2005) [Pubmed]
  7. Inhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel disease. Crotty, B., Rosenberg, W.M., Aronson, J.K., Jewell, D.P. Gut (1992) [Pubmed]
  8. Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group. Kiilerich, S., Ladefoged, K., Rannem, T., Ranløv, P.J. Gut (1992) [Pubmed]
  9. Effects of olsalazine and sulphasalazine on jejunal and ileal water and electrolyte absorption in normal human subjects. Raimundo, A.H., Patil, D.H., Frost, P.G., Silk, D.B. Gut (1991) [Pubmed]
  10. Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Lewis, L.D., Benin, A., Szumlanski, C.L., Otterness, D.M., Lennard, L., Weinshilboum, R.M., Nierenberg, D.W. Clin. Pharmacol. Ther. (1997) [Pubmed]
  11. Endogenous antioxidant status in neoplastic and adjacent tissues in 1,2-dimethylhydrazine-induced colon cancer in rats: effects of olsalazine. Moghadasian, M.H., Freeman, H.J., Godin, D.V. Carcinogenesis (1996) [Pubmed]
  12. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Mantzaris, G.J., Sfakianakis, M., Archavlis, E., Petraki, K., Christidou, A., Karagiannidis, A., Triadaphyllou, G. Am. J. Gastroenterol. (2004) [Pubmed]
  13. Antihistone antibody profile in sulfasalazine induced lupus. Bray, V.J., West, S.G., Schultz, K.T., Boumpas, D.T., Rubin, R.L. J. Rheumatol. (1994) [Pubmed]
  14. Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis. Lauritsen, K., Staerk Laursen, L., Bukhave, K., Rask-Madsen, J. Gut (1988) [Pubmed]
  15. Influence of olsalazine on gastrointestinal transit in ulcerative colitis. Rao, S.S., Read, N.W., Holdsworth, C.D. Gut (1987) [Pubmed]
  16. The effects of sulfasalazine metabolites on hemoglobin-catalyzed lipid peroxidation. Yamada, T., Volkmer, C., Grisham, M.B. Free Radic. Biol. Med. (1991) [Pubmed]
  17. Effects of aminosalicylates and immunosuppressive agents on nitric oxide-dependent N-nitrosation reactions. Grisham, M.B., Miles, A.M. Biochem. Pharmacol. (1994) [Pubmed]
  18. Comparative bioavailability of 5-aminosalicylic acid from a controlled release preparation and an azo-bond preparation. Christensen, L.A., Fallingborg, J., Jacobsen, B.A., Abildgaard, K., Rasmussen, H.H., Hansen, S.H., Rasmussen, S.N. Aliment. Pharmacol. Ther. (1994) [Pubmed]
  19. Effect of azodisal sodium and sulphasalazine on ileostomy output of fluid and PGE2 and PGF2 alpha in subjects with a permanent ileostomy. Sandberg-Gertzén, H., Järnerot, G., Bukhave, K., Lauritsen, K., Rask-Madsen, J. Gut (1986) [Pubmed]
  20. Effects of olsalazine in the jejunum of the rat. Mohsen, A.Q., Mulvey, D., Priddle, J.D., Parsons, D.S., Jewell, D.P. Gut (1987) [Pubmed]
  21. Inhibition of intestinal macrophage chemotaxis to leukotriene B4 by sulphasalazine, olsalazine, and 5-aminosalicylic acid. Nielsen, O.H., Verspaget, H.W., Elmgreen, J. Aliment. Pharmacol. Ther. (1988) [Pubmed]
  22. Drug interactions in intestinal transport of folic acid and methotrexate. Further evidence for the heterogeneity of folate transport in the human small intestine. Zimmerman, J. Biochem. Pharmacol. (1992) [Pubmed]
  23. Disposition of olsalazine and metabolites in breast milk. Miller, L.G., Hopkinson, J.M., Motil, K.J., Corboy, J.E., Andersson, S. Journal of clinical pharmacology. (1993) [Pubmed]
  24. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. Klotz, U., Schwab, M. Adv. Drug Deliv. Rev. (2005) [Pubmed]
  25. Azodisalicylate (azodisal sodium) causes intestinal secretion. Comparative study of the effect of azodisalicylate, sulfasalazine, 5-aminosalicylic acid and sulfapyridine on the water and electrolyte transfer and the morphology of the rat ileum and colon in vivo. Goerg, K.J., Wanitschke, R., Gabbert, H., Breiling, J., Franke, M., Meyer zum Büschenfelde, K.H. Digestion (1987) [Pubmed]
  26. Olsalazine in ankylosing spondylitis: a pilot study. Chapman, C.M., Zwillich, S.H. J. Rheumatol. (1994) [Pubmed]
  27. Pancreatitis associated with olsalazine and sulfasalazine in children with ulcerative colitis. Garau, P., Orenstein, S.R., Neigut, D.A., Kocoshis, S.A. J. Pediatr. Gastroenterol. Nutr. (1994) [Pubmed]
  28. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial. Feurle, G.E., Theuer, D., Velasco, S., Barry, B.A., Wördehoff, D., Sommer, A., Jantschek, G., Kruis, W. Gut (1989) [Pubmed]
  29. Systemic availability of 5-aminosalicylic acid: comparison of delayed release and an azo-bond preparation. Gionchetti, P., Campieri, M., Venturi, A., Rizzello, F., Ferretti, M., Brignola, C., Miglioli, M. Aliment. Pharmacol. Ther. (1996) [Pubmed]
WikiGenes - Universities